Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | RAD52 | P43351 | 2/20 | 0.60 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | CTSD | P07339 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.59 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560127 | 0.83 | HPGD (0.55) | ALDH1A1HPGDTP53GLACTSD | |
| SCHEMBL6360123 | 0.83 | HPGD (0.65) | ALDH1A1HPGDTP53GLACTSD | |
| SCHEMBL11761482 | 0.83 | NAMPT (0.71) | ALDH1A1HPGDTP53GLACTSD | |
| SCHEMBL3038950 | 0.83 | KMT2A (0.74) | ALDH1A1HPGDTP53GLACTSD | |
| SCHEMBL20125128 | 0.82 | HTT (0.68) | ALDH1A1KDM4ERAD52SMARCA2MCHR1 | |
| SCHEMBL10243095 | 0.81 | STAT3 (0.64) | ALDH1A1HPGDTP53GLACTSD | |
| SCHEMBL7956519 | 0.81 | HPGD (0.63) | ALDH1A1HPGDTP53GLACTSD | |
| SCHEMBL3365176 | 0.81 | CTSD (0.68) | ALDH1A1HPGDTP53GLACTSD | |
| SCHEMBL30848493 | 0.81 | HPGD (0.63) | ALDH1A1HPGDTP53GLACTSD | |
| SCHEMBL13886660 | 0.81 | MCHR1 (0.68) | ALDH1A1RAD52HPGDMCHR1UHRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | ALDH1A1 2240/4885KDM4E 192/4885RAD52 4644/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | ALDH1A1 785/4885KDM4E 861/4885RAD52 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.